Year: 2025
MT Højgaard Holding has today entered into an agreement to sell its last business activity in Greenland, the technical contracting and service company Arssarnerit. The sale is expected to be completed in the second quarter of 2026, subject to the approval of the competition authorities.
The buyer is VVS & El Firmaet A/S, which will take over all activities in Arssarnerit, including operating assets, inventory, ongoing projects, employees and guarantees for completed projects up to a certain limit. The price for the sold assets and liabilities corresponds to the book value.
Prior to entering into the agreement, MT Højgaard Holding has divested the HVAC service business and all activities outside Nuuk to focus Arssarnerit on its original core business of technical contracting activities in the Nuuk area. This is the activity that VVS...
CHAR Technologies Announces Closing of Book on Fully Subscribed Private Placement
Written by Customer Service on . Posted in Public Companies.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — CHAR Technologies Ltd. (“CHAR Tech” or the “Company”) (TSXV:YES), a leader in sustainable energy solutions, is pleased to announce that the Company has closed the order book on its previously announced non-brokered private placement (the “Offering”) of 5,000,000 units (each, a “Unit”) at a price of $0. 20 CAD per Unit for aggregate gross proceeds of$1 million CAD.
The Offering has been fully subscribed with institutional investor representation. The closing is expected to occur by or around the end of the week of December 16th, or a later date that may be determined by the Company. The Offering is subject to certain closing conditions, including, but not limited to, the receipt of all necessary...
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
Written by Customer Service on . Posted in Public Companies.
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
In the STEP UP programme, people with obesity taking Wegovy® 7.2 mg lost an average of 20.7% body weight at 72 weeks; one in three people achieved 25% or more weight loss1*
The higher dose adds a new option for substantial weight loss while preserving muscle function and maintaining the established cardiovascular health benefits of Wegovy®2Bagsværd, Denmark, 12 December 2025 – Today, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy® (semaglutide 7.2 mg), bringing it a step closer to offering individuals with obesity in the EU a new Wegovy® option for even greater weight loss. The new dose...
EdgeMode Announces Strategic Portfolio Review and Advancement of AI Data Center Development Pipeline in Spain
Written by Customer Service on . Posted in Public Companies.
FORT LAUDERDALE, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) — EdgeMode, Inc. (OTC: EDGM) (“EdgeMode” or the “Company”) today announced the results of a recent internal review of certain legacy arrangements and provided an update on its expanding AI Data Center development portfolio in Spain.
Internal Review of Legacy Agreements
As part of a routine internal review, the Company identified issues within a Share exchange agreement completed earlier this year. The Company has issued notice of its intention to pursue rescission of that agreement based on information recently discovered. While the rescission process is subject to formal procedures and may require judicial action, the Company has taken the initial steps toward unwinding the transaction.
The potential impact of this action represents less than 5.5% of the Company’s total AI...
LOBO Announces Integration of Experienced Solar Team into Jiangsu LOBO; Represents a Strong Entry into the PV Energy Storage Power Generation Sector
Written by Customer Service on . Posted in Public Companies.
WUXI, China, Dec. 12, 2025 (GLOBE NEWSWIRE) — LOBO TECHNOLOGIES LTD. (NASDAQ: LOBO) (“LOBO” or the “Company”), a developer and manufacturer of electric mobility and smart energy solutions, today announced that its operating subsidiary, Jiangsu LOBO Electric Vehicle Co. Ltd. (“Jiangsu LOBO”), has onboarded the entire team of Shenzhen Xiangri Technology Co., Ltd. (“Shenzhen Xiangri”), including its research & development, sales and business operation teams. This integration establishes a new Solar Division within Jiangsu LOBO, decided to advance the Company’s entry into the photovoltaic (“PV”) energy-storage power generation market.
Founded in 2012, the Shenzhen Xiangri team brings over twelve years of expertise in the solar PV industry, with a focus of manufacturing solar modules and delivering integrated system solutions....
DSV – CAPITAL MARKETS DAY 2026
Written by Customer Service on . Posted in Public Companies.
We would like to invite institutional investors and analysts to attend our Capital Markets Day on 12 May 2026.
A detailed programme will follow, but please mark this date in your calendar. The Capital Markets Day will be a hybrid event with live streaming. A recording of the Capital Markets Day will be made available on our investor website after the event. Please note that there are limited seats available for physical attendance.
Date: Tuesday, 12 May 2026
Location: DSV, Hedehusene 630, 2640 Hedehusene, Denmark
Sign-up for more information here: DSV Capital Markets Day 2026 – Sign up for more information
ContactsInvestor Relations:
Veronica Pontoppidan, IR Coordinator, tel. +45 41 11 06 46, veronica.pontoppidan@dsv.com
Yours sincerely,DSV A/SAttachmentINVESTOR NEWS – DSV CAPITAL MARKETS DAY 2026
VCI Global Concludes ELOC to Simplify Capital Structure and Prepare for Multi-Subsidiary Listings
Written by Customer Service on . Posted in Mergers And Acquisitions.
Enhance Capital Structure Supports Digital Asset Treasury Expansion and Institutional-Grade Growth Strategy
KUALA LUMPUR, Malaysia, Dec. 12, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced the conclusion of its Equity Line of Credit (ELOC) facility. This strategic move streamlines the Company’s capital structure and positions the Company to concentrate on its highest-priority growth areas, including its Digital Asset Treasury (DaT) initiatives and its enterprise data and AI operations. VCI Global is well positioned to execute a disciplined, institutional-grade growth strategy across its technology and infrastructure businesses.
Focused Growth on Digital Asset Treasury and Enterprise AI Operations
VCI Global remains committed to advancing its enterprise data and AI...
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
Written by Customer Service on . Posted in Public Companies.
HIGHLIGHTSAn additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Sciences Virtual Investor ForumMelbourne, Australia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial in metastatic pancreatic cancer. The trial investigates the combination of the Company’s best-in-class FAK inhibitor narmafotinib in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®).
The additional PR brings the confirmed objective response rate (ORR) to 35% (19/55) which compares favourably to the ORR of 23% recorded for...
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Written by Customer Service on . Posted in Public Companies.
Final Decision from European Commission Expected in Q1 2026
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026.
“We are pleased with CHMP’s positive recommendation based on the robust clinical evidence from SEQUOIA-HCM that demonstrated the safety and efficacy of MYQORZO in patients...
Rail Vision: Quantum AI Powers Next-Gen Rail Safety Breakthroughs
Written by Customer Service on . Posted in Public Companies.
Rail Vision Enters the Quantum Transportation Market with Strategic Acquisition Agreement
Ra’anana, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, recently announced the signing of an agreement for a strategic transaction to acquire 51% ownership of Quantum Transportation Ltd. (the “Acquisition” and “Quantum Transportation”), a cutting-edge quantum computing and AI company specializing in error correction technologies. The closing of the Acquisition is expected to close in late December 2025 to early January 2026, subject to the satisfaction of customary closing conditions.
Quantum Transportation holds an exclusive sublicense, for rail technologies...
